Cliff Asness's PBYI Position Overview
Cliff Asness (via Aqr Capital Management LLC) currently holds 725,192 shares of Puma Biotechnology, Inc. (PBYI) worth $5.88 M, representing 0.00% of the portfolio. First purchased in 2012-Q4, this long-term strategic position has been held for 30 quarters.
Based on 13F filings, Cliff Asness has maintained a strategic position in PBYI, demonstrating sustained confidence in this investment. Largest addition occurred in Q4 2025, adding 535,933 shares. Largest reduction occurred in Q3 2014, reducing 90,400 shares.
Analysis based on 13F filings available since 2013 Q2
Cliff Asness's Puma Biotechnology (PBYI) Holding Value Over Time
Track share changes against reported price movement
Quarterly Puma Biotechnology (PBYI) Trades by Cliff Asness
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q2 2026 | -75,002 | Reduce 9.37% | 725,192 | $8.11 |
| Q1 2026 | +133,589 | Add 20.04% | 800,194 | $6.39 |
| Q4 2025 | +535,933 | Add 410.14% | 666,605 | $5.95 |
| Q3 2025 | -11,101 | Reduce 7.83% | 130,672 | $5.31 |
| Q2 2025 | +91,315 | Add 180.97% | 141,773 | $3.43 |
| Q1 2025 | +39,641 | Add 366.47% | 50,458 | $2.96 |
| Q4 2024 | +10,817 | New Buy | 10,817 | $3.05 |
| Q4 2018 | -29,911 | Sold Out | 0 | $0.00 |
| Q3 2018 | -14,912 | Reduce 33.27% | 29,911 | $45.84 |
| Q2 2018 | +951 | Add 2.17% | 44,823 | $59.14 |
| Q1 2018 | -1,349 | Reduce 2.98% | 43,872 | $68.04 |
| Q4 2017 | -3,040 | Reduce 6.30% | 45,221 | $98.85 |
| Q3 2017 | +30,056 | Add 165.10% | 48,261 | $119.74 |
| Q2 2017 | +18,205 | New Buy | 18,205 | $87.39 |
| Q3 2016 | -13,410 | Sold Out | 0 | $0.00 |
| Q2 2016 | +3,513 | Add 35.50% | 13,410 | $29.75 |
| Q1 2016 | +334 | Add 3.49% | 9,897 | $29.40 |
| Q4 2015 | -11,678 | Reduce 54.98% | 9,563 | $78.43 |
| Q3 2015 | -4,782 | Reduce 18.38% | 21,241 | $75.37 |
| Q2 2015 | +9,272 | Add 55.35% | 26,023 | $116.74 |
| Q1 2015 | -1,200 | Reduce 6.68% | 16,751 | $236.11 |
| Q4 2014 | +2,662 | Add 17.41% | 17,951 | $189.24 |
| Q3 2014 | -90,400 | Reduce 85.53% | 15,289 | $238.54 |
| Q2 2014 | +68,300 | Add 182.67% | 105,689 | $66.00 |
| Q1 2014 | -25,800 | Reduce 40.83% | 37,389 | $104.15 |
| Q4 2013 | +1,373 | Add 2.22% | 63,189 | $103.53 |
| Q3 2013 | +54,501 | Add 745.06% | 61,816 | $53.66 |
| Q2 2013 | +7,315 | Add 0.00% | 7,315 | $44.43 |
| Q4 2012 | +38,327 | Add 0.00% | 38,327 | $18.76 |
Cliff Asness's Puma Biotechnology Investment FAQs
Cliff Asness first purchased Puma Biotechnology, Inc. (PBYI) in Q4 2012, acquiring 38,327 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Cliff Asness has held Puma Biotechnology, Inc. (PBYI) for 30 quarters since Q4 2012.
Cliff Asness's largest addition to Puma Biotechnology, Inc. (PBYI) was in Q4 2025, adding 666,605 shares worth $3.97 M.
According to the latest 13F filing for Q2 2026, Cliff Asness's firm, Aqr Capital Management LLC, owns 725,192 shares of Puma Biotechnology, Inc. (PBYI), valued at approximately $5.88 M.
As of the Q2 2026 filing, Puma Biotechnology, Inc. (PBYI) represents approximately 0.00% of Cliff Asness's publicly disclosed stock portfolio, making it one of their key holdings.
Cliff Asness's peak holding in Puma Biotechnology, Inc. (PBYI) was 800,194 shares, as reported at the end of Q1 2026.